N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance

Ma MJ, Shi YH, Liu ZD, Zhu YQ, Zhao GY, Ye JY, Li FX, Huang XT, Wang XY, Wang JQ, Xu QC, Yin XY. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Oncogene. 2024 Jun 24. doi: 10.1038/s41388-024-03092-3. Epub ahead of print. PMID: 38914663.

Used in this study: B-NDG mice